Bio-Techne ( (TECH) ) has realeased its Q1 earnings. Here is a breakdown of the information Bio-Techne presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Bio-Techne Corporation is a global life sciences company that specializes in providing innovative tools and bioactive reagents for research and clinical diagnostics, aiding scientific investigations, drug discovery efforts, and clinical testing. In its first quarter fiscal 2025 results, Bio-Techne reported a 5% increase in net sales to $289.5 million, with organic growth at 4%, reflecting strong segment performance, particularly in Diagnostics and Spatial Biology, which grew by 14%. The company’s adjusted EPS slightly increased to $0.42, while GAAP EPS declined from $0.31 to $0.21, impacted by restructuring-related charges. Notably, the Diagnostics and Spatial Biology segment showed significant growth, driven by increased utilization of its portfolio and productivity initiatives, while the Protein Sciences segment remained stable. Despite challenges, the company continues to focus on its growth pillars, emphasizing strong performance in cell and gene therapy solutions. Looking ahead, Bio-Techne remains optimistic about a recovery in its biotech end market and is committed to delivering value through its innovative solutions, positioned for future growth in the industry.
